|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RABL6 |
Gene summary for RABL6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RABL6 | Gene ID | 55684 |
| Gene name | RAB, member RAS oncogene family like 6 | |
| Gene Alias | C9orf86 | |
| Cytomap | 9q34.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | H0Y4Z8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55684 | RABL6 | LZE7T | Human | Esophagus | ESCC | 1.57e-07 | 4.72e-01 | 0.0667 |
| 55684 | RABL6 | LZE20T | Human | Esophagus | ESCC | 1.00e-06 | 3.73e-01 | 0.0662 |
| 55684 | RABL6 | LZE22T | Human | Esophagus | ESCC | 6.88e-07 | 3.26e-01 | 0.068 |
| 55684 | RABL6 | LZE24T | Human | Esophagus | ESCC | 6.17e-08 | 1.96e-01 | 0.0596 |
| 55684 | RABL6 | LZE21T | Human | Esophagus | ESCC | 4.20e-06 | 4.26e-01 | 0.0655 |
| 55684 | RABL6 | P1T-E | Human | Esophagus | ESCC | 8.81e-09 | 4.92e-01 | 0.0875 |
| 55684 | RABL6 | P2T-E | Human | Esophagus | ESCC | 4.97e-71 | 1.18e+00 | 0.1177 |
| 55684 | RABL6 | P4T-E | Human | Esophagus | ESCC | 1.06e-22 | 4.71e-01 | 0.1323 |
| 55684 | RABL6 | P5T-E | Human | Esophagus | ESCC | 3.61e-20 | 3.91e-01 | 0.1327 |
| 55684 | RABL6 | P8T-E | Human | Esophagus | ESCC | 3.89e-15 | 3.02e-01 | 0.0889 |
| 55684 | RABL6 | P9T-E | Human | Esophagus | ESCC | 3.87e-10 | 2.45e-01 | 0.1131 |
| 55684 | RABL6 | P10T-E | Human | Esophagus | ESCC | 1.64e-24 | 3.64e-01 | 0.116 |
| 55684 | RABL6 | P11T-E | Human | Esophagus | ESCC | 1.32e-02 | 2.03e-01 | 0.1426 |
| 55684 | RABL6 | P12T-E | Human | Esophagus | ESCC | 7.18e-13 | 1.45e-01 | 0.1122 |
| 55684 | RABL6 | P15T-E | Human | Esophagus | ESCC | 2.58e-09 | 2.42e-01 | 0.1149 |
| 55684 | RABL6 | P16T-E | Human | Esophagus | ESCC | 8.98e-15 | 1.73e-01 | 0.1153 |
| 55684 | RABL6 | P17T-E | Human | Esophagus | ESCC | 3.65e-05 | 1.75e-01 | 0.1278 |
| 55684 | RABL6 | P20T-E | Human | Esophagus | ESCC | 1.83e-08 | 9.57e-02 | 0.1124 |
| 55684 | RABL6 | P21T-E | Human | Esophagus | ESCC | 8.14e-17 | 3.04e-01 | 0.1617 |
| 55684 | RABL6 | P22T-E | Human | Esophagus | ESCC | 1.00e-17 | 2.47e-01 | 0.1236 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RABL6 | SNV | Missense_Mutation | c.804N>G | p.Asn268Lys | p.N268K | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A1F2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| RABL6 | SNV | Missense_Mutation | c.1717N>T | p.Asp573Tyr | p.D573Y | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | ||
| RABL6 | SNV | Missense_Mutation | rs777136840 | c.586G>A | p.Asp196Asn | p.D196N | protein_coding | tolerated(0.07) | benign(0.005) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RABL6 | SNV | Missense_Mutation | novel | c.776N>T | p.Ser259Leu | p.S259L | protein_coding | deleterious(0.04) | probably_damaging(0.938) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RABL6 | SNV | Missense_Mutation | c.18G>T | p.Lys6Asn | p.K6N | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-3L-AA1B-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| RABL6 | SNV | Missense_Mutation | c.190N>A | p.Gln64Lys | p.Q64K | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR | ||
| RABL6 | SNV | Missense_Mutation | c.1175N>T | p.Glu392Val | p.E392V | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| RABL6 | SNV | Missense_Mutation | rs559366258 | c.1646N>C | p.Glu549Ala | p.E549A | protein_coding | tolerated_low_confidence(0.26) | benign(0.14) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| RABL6 | SNV | Missense_Mutation | rs371358921 | c.625C>T | p.Arg209Cys | p.R209C | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-CM-6169-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Ancillary | leucovorin | SD | |
| RABL6 | SNV | Missense_Mutation | rs771039241 | c.919N>A | p.Ala307Thr | p.A307T | protein_coding | tolerated(0.44) | benign(0) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |